Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Debt to Equity (2020 - 2022)

RedHill Biopharma has reported Debt to Equity over the past 3 years, most recently at -$2.38 for Q4 2022.

  • Quarterly Debt to Equity fell 112.63% to -$2.38 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$2.38 through Dec 2022, down 112.63% year-over-year, with the annual reading at -$2.38 for FY2022, 112.63% down from the prior year.
  • Debt to Equity was -$2.38 for Q4 2022 at RedHill Biopharma, down from $18.84 in the prior quarter.
  • Over five years, Debt to Equity peaked at $18.84 in Q4 2021 and troughed at -$2.38 in Q4 2022.
  • The 3-year median for Debt to Equity is $11.74 (2020), against an average of $9.4.
  • Year-over-year, Debt to Equity soared 60.5% in 2021 and then crashed 112.63% in 2022.
  • A 3-year view of Debt to Equity shows it stood at $11.74 in 2020, then skyrocketed by 60.5% to $18.84 in 2021, then crashed by 112.63% to -$2.38 in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Debt to Equity are -$2.38 (Q4 2022), $18.84 (Q4 2021), and $11.74 (Q4 2020).